

# Pressure BioSciences, Inc.

16:00 16 May 2019

## Pressure BioSciences 1Q revenue boosted by new BioPharma contract services, Ultra Shear Technology platform

Pressure BioSciences Inc (OTCMKTS:PBIO) posted first-quarter results Thursday that showed substantial new revenue generated from its Ultra Shear Technology platform and just launched Biopharma contract services business.

The commercial launch of the BioPharma contract services business follows Pressure BioSciences' acquisition of BaroFold Inc's assets, which included patents and equipment linked to Barofold's high pressure-based protein disaggregation and refolding platform.

The company's Pressure Cycling Technology and BaroFold platform technologies can help companies produce new and improved protein-based therapeutic drugs, a market that is expected to reach \$240 billion dollars by 2023.

### READ: Pressure BioSciences showcases abilities of Ultra Shear Technology platform to improve CBD oil

For the quarter ended March 2019, the South Easton, Massachusetts-based company clocked total revenue of \$510,000. The new BioPharma and Ultra Shear Technology platform contract services contributed nearly \$238,000, whereas there was no services revenue in the same period a year ago.

"We believe strongly that the deliberate shift in our sales strategy and new emergent contract services area will both result in increased revenue growth through the current fiscal year," said Pressure BioSciences CEO Richard T Schumacher in a statement. "We are moving quickly with new business leadership under Dr Bradford Young and are actively recruiting sales representatives to fill out our team."

Schumacher said the quarter marked a "shift in the focus" of the company's sales strategy from academics and opinion leaders to more "lucrative and efficient" long-term growth relationships with biopharmaceutical companies.

### New growth areas

"We are increasing our strategic focus and resources on our two new growth areas: contract services related to the BaroFold and UST platforms," said Schumacher.


Operating loss for the first quarter increased by 26% to \$1,397,000 compared to \$1,108,000 for the corresponding period a year ago.

"We placed a large amount of effort and focus on our new Biopharma and UST contract services with very encouraging results," said Dr Bradford Young, chief commercial officer at Pressure BioSciences. "We will continue to emphasize these key strategic growth initiatives going forward."

**Price:** 2.03

**Market Cap:** \$7.89 m

#### 1 Year Share Price Graph



December 2019 June 2020 December 20

#### Share Information

**Code:** PBIO

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.49	0.6006

**Sector:** Medical technology & services

**Website:** www.pressurebiosciences.com

#### Company Synopsis:

*Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.*

action@proactiveinvestors.com

Young said the markets for the company's proprietary technology platforms are "very large" and will continue to grow.

### **UST platform technology**

"We anticipate that the growing use of these new services will also support increased sales of our Pressure Cycling Technology instruments and consumables," said Young.

The company recently demonstrated the ability of its proprietary UST platform to create water-soluble CBD Oil that disperses instantly when infused into soft drinks, sports drinks, and beer for quick absorption.

Pressure BioSciences already holds two patents for Ultra Sheer Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The advanced technology allows companies to extend the life of milk, and healthier drinks and juices, by reducing heat exposure in the preservation process through a combined application of elevated pressure and controlled times and temperatures.

Ultra Sheer Technology also utilizes high pressure to create intense, momentary liquid shearing forces at controlled temperatures that result in affordable and scalable homogenization of liquids, creams and gels. The technology creates nano-scale emulsion mixtures of otherwise immiscible fluids like oils in water that results in stable homogenized products called nanoemulsions. As a result, the technology has wide potential uses in the pharmaceutical, industrial ink, retail and cosmetics industry.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).